Skip to main content
Year archive

Formycon AG — 2021 filings

All 31 regulatory filings released by Formycon AG (FYB) in 2021, sourced directly from the official regulator.

31 Filings
2021 Period
2021 filings (31)
Filing Released Lang
MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region
Regulatory Filings
2021-12-14 English
Formycon and Scientists from TUM publish new Data on broadly effective SARS-CoV-2 antiviral Drug FYB207
Investor Presentation
2021-12-09 English
Formycon Reports its Nine-Month Figures for 2021
Earnings Release 9M 2021
2021-11-09 English
Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
Regulatory Filings
2021-10-19 English
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Regulatory Filings
2021-10-18 English
Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
Legal Proceedings Report
2021-10-01 English
Formycon Reports on Virtual Annual General Meeting 2021
AGM Information
2021-09-27 English
Formycon Publishes Half-Year Results for 2021
Earnings Release H1 2021
2021-09-21 English
Half-yearly financial statements 2021
Interim / Quarterly Report H1 2021
2021-09-21 German
Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021
Regulatory Filings
2021-09-15 English
Formycon reports on the status of FYB207 development
Regulatory Filings
2021-08-11 English
Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
Legal Proceedings Report
2021-08-05 English
Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
Legal Proceedings Report
2021-07-12 English
Formycon Reports Financial Results for the First Quarter of 2021
Earnings Release Q1 2021
2021-06-30 English
Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
Regulatory Filings
2021-06-29 English
Formycon announces conclusion of exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. for FYB201 in Europe, Canada, Israel and New Zealand
Regulatory Filings
2021-06-28 English
Formycon Publishes Annual Financial Statements for the 2020 Financial Year
Earnings Release FY 2020
2021-05-17 English
Annual financial statements 2020
Annual Report FY 2020
2021-05-17 German
Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi)
Regulatory Filings
2021-04-27 English
Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7
Regulatory Filings
2021-03-25 English
Formycon and Leukocare cooperate in the development of high-quality biopharmaceuticals
Regulatory Filings
2021-03-24 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-03-05 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-03-05 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-03-05 English
Formycon confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* Biosimilar-Candidate FYB201 following consultation with the FDA
Regulatory Filings
2021-03-01 English
Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities
Regulatory Filings
2021-02-24 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-02-05 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-02-05 English
DGAP-DD: Formycon AG english
Director's Dealing
2021-02-05 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Annual Report FY 2019
2021-02-01 German
Formycon's Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium
Regulatory Filings
2021-01-13 English